Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 4Terminated 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 1

Conditions

Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 2Recurrence 1Psoriasis 1Neoplasms 1Lymphoma, Follicular 1Inflammatory Bowel Diseases 1Colonic Neoplasms 1Colitis, Ulcerative 1Adenoma 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Mesalamine × Clear all
NCT04920149 2024-12-17

MesaCAPP

Karolinska University Hospital

Phase 2 Recruiting
150 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis

NCT02093663 2021-06-09

PACE

Takeda

Phase 3 Completed
107 enrolled 18 charts
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

NCT03070574 2019-04-18

MesaCAPP

Medical University of Vienna

Phase 2 Terminated
8 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02077777 2016-12-02

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

SOFAR S.p.A.

Phase 2 Completed
21 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01894685 2015-12-08

Mesalazine Effects in Sporadic Colorectal Adenoma Patients

UMC Utrecht

Phase 2 Completed
74 enrolled

Adenoma, Recurrence

NCT02376478 2015-03-03

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Medical University of Vienna

Completed
222 enrolled

Psoriasis, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡